CA-TRIVVER
14.5.2018 10:02:10 CEST | Business Wire | Press release
Trivver , the premiere advertising exchange for Extended Reality (XR) environments including 3D, virtual reality, mixed reality and augmented reality, today announced that it will launch the sale of up to 100 million Trivver Tokens (TRVR) to accelerate the adoption, commercialization and monetization of XR technology across devices and industries for all stakeholders in the ecosystem – including content publishers, advertisers, brands, agencies and consumers.
Current 2D advertising tactics like pop-ups, banners, video and interstitials are highly disruptive to immersive XR experiences, leading to limited advertiser adoption of XR and reduced monetization opportunities for XR developers and publishers. Placing ads organically within the natural settings of XR environments is the answer, but the current processes that developers, publishers and advertisers use to execute this strategy is tedious and costly, as ads and objects need to be manually resized to fit each unique location. With Trivver’s suite of patented technology, including its core Smart Object Technology, developers are able to create and deliver native advertising directly into XR environments. This approach enables advertisers to create contextual, integrated XR ad campaigns to engage consumers in a unique and impactful way and gives publishers the opportunity to efficiently monetize their XR content.
“We believe in the exponential possibilities of XR and in the profound, lasting and global impact of this technology,” said Joel LaMontagne, CEO of Trivver. “We are passionate about driving XR adoption among consumers and within the enterprise. Our goal is to enable publishers and developers in the XR space to fund themselves through advertising and encourage the improvement of technology that enhances XR experiences for consumers. We’re also making it easier for advertisers to promote their brand in the XR space through seamless product placement – delivering relevant and interesting content to engage their users.”
In order to drive XR adoption and momentum, Trivver launched its pre-sale of TRVR tokens, which can be purchased with a bonus until June 5, 2018. The public token sale begins on June 8, 2018 and will close on July 7, 2018. The public sale will aim to raise $35 million, with the pre-sale accounting for up to $5 million.
Token Sale Details:
- Under the terms of the sale, 1 ETH is equivalent to 750 TRVR (1 TRVR ~ 0.00133 ETH) and a hard cap of 100 million TRVR tokens are available for purchase of the finite supply of 200 million total TRVR.
- All available TRVR will be issued during the distribution period, of which, 50 percent will be allocated to the public and 50 percent will be allocated to the reserve to be held by the company and used to stimulate growth in the Trivver XR advertising ecosystem by rewarding participants with TRVR.
- All TRVR not distributed will be burned.
TRVR is the currency for the Smart Object Economy. Trivver’s patented Branded Smart Objects (BSOs) are 3D objects with product information (SKU data, coupons, social media links etc.) that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment. Trivver’s BSOs send valuable viewability and user engagement metrics back to the advertiser that will result in the best ROI.
Trivver launched its token sale in order to accelerate the build out of its Smart Objects catalog and will incentivize developers to participate through a system of rewards and payments of TRVR. Developers can earn TRVR for building and adding smart objects to the catalog. They can also use TRVR to list the smart object in Trivver’s inventory and establish authorship of the object. As the author, developers will receive royalties paid in USD from Trivver whenever revenues are generated by the smart object - from a publisher using it to build XR content or by an advertiser using it for future XR ad campaigns.
The Trivver platform is currently in beta and the company has already seen significant interest, announcing upcoming pilot programs in collaboration with WayFair and Cannon.
To learn more about Trivver and to participate in the token sale, visit: https://www.trivver.com/tokensale or join the conversation on Telegram to speak directly with the project’s founders and developers: https://t.me/trivvertokensale . Download the token sale whitepaper at: https://www.trivver.com/docs/Trivver_Whitepaper.pdf .
About Trivver
Trivver is the premiere advertising exchange for Extended Reality (XR) environments – 3D, virtual reality, mixed reality and augmented reality. The Trivver platform makes creating and deploying 3D interactive branded objects easier, allowing brands to programmatically execute targeted, impactful and scalable XR campaigns.
Trivver’s revolutionary, patented Branded Smart Objects (BSOs) are 3D objects that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment.
The Trivver XR Ad Exchange (XRAE) is a programmatic solution that lets advertisers create, run and monitor a highly targeted XR ad campaign in near real time, on mobile apps and desktop applications. Trivver enables publishers to monetize XR environments with branded content that is native and organic – eliminating pop-ups, banners and interstitials that are disruptive to user experience. The Trivver platform facilitates an organic relationship between brand and consumer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514005068/en/
Contact:
Affect
Nicole Sullivan, 212-398-9680
trivver@affect.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
